CANSINOBIO (06185) experienced a significant surge in its stock price, soaring 5.01% during intraday trading on Friday. The sharp increase comes on the heels of the company's impressive third-quarter financial results, which showcased substantial growth in both revenue and profitability.

According to the company's latest financial report, CANSINOBIO's Q3 revenue reached RMB310 million, marking a 17.67% year-over-year increase. More notably, the net profit attributable to shareholders skyrocketed by an astounding 842.01% compared to the same period last year, reaching RMB27.93 million. This remarkable performance extends beyond the quarter, with the first nine months of the year showing a 22.13% year-over-year revenue increase to RMB693 million, and a return to profitability with a net profit of RMB14.44 million.

The driving force behind CANSINOBIO's stellar performance is the strong market uptake of its core product, MenHibrix. As the only quadrivalent meningococcal conjugate vaccine available in China's meningitis vaccine market, MenHibrix's innovative advantages have significantly boosted the company's market share. The product's success has been instrumental in fueling the company's revenue growth and profitability, leading to increased investor confidence and the subsequent stock price surge.